Anaptys To Provide Overview Of Rosnilimab, A PD-1 Agonist, At Virtual R&D Event On Wednesday, Oct. 25
Portfolio Pulse from Benzinga Newsdesk
AnaptysBio, Inc. (NASDAQ:ANAB) will host a virtual R&D event on October 25 to provide an overview of rosnilimab, a PD-1 agonist antibody. The event will include discussions on PD-1 biology, rosnilimab's mechanism of action, and Phase 2 development plans for rheumatoid arthritis and a second indication to be unveiled during the webcast. Rosnilimab is a novel PD-1 checkpoint agonist antibody that reduces overactive T cell inflammation.
October 09, 2023 | 12:19 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
AnaptysBio's upcoming R&D event could potentially impact the company's stock as it will provide insights into the development of rosnilimab, a PD-1 agonist antibody.
The R&D event will provide insights into the development of rosnilimab, a PD-1 agonist antibody. This could potentially impact investor sentiment and the company's stock price, especially if the Phase 2 development plans are promising.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100